The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 10, 2023
Filed:
Oct. 31, 2019
Applicant:
Lunella Biotech, Inc., Ottawa, CA;
Inventors:
Michael P. Lisanti, Fulton, MD (US);
Federica Sotgia, Fulton, MD (US);
Assignee:
LUNELLA BIOTECH, INC., Ontario, CA;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/55 (2006.01); C07D 403/04 (2006.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01); A61K 31/137 (2006.01); C07D 295/135 (2006.01); C07C 217/74 (2006.01); C07D 223/04 (2006.01); C07D 401/04 (2006.01); C07C 235/46 (2006.01); C07D 491/107 (2006.01); C07C 275/24 (2006.01); C07D 513/04 (2006.01); C07D 207/06 (2006.01); A61P 15/16 (2006.01); A61K 31/14 (2006.01); A61K 31/155 (2006.01); A61K 31/66 (2006.01); G16C 20/50 (2019.01); A61K 9/00 (2006.01); A61K 31/40 (2006.01); A61K 31/436 (2006.01); A61K 31/519 (2006.01); A61K 31/5513 (2006.01);
U.S. Cl.
CPC ...
A61K 31/137 (2013.01); A61K 31/14 (2013.01); A61K 31/155 (2013.01); A61K 31/66 (2013.01); A61P 15/16 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); C07C 217/74 (2013.01); C07C 235/46 (2013.01); C07C 275/24 (2013.01); C07D 207/06 (2013.01); C07D 223/04 (2013.01); C07D 295/135 (2013.01); C07D 401/04 (2013.01); C07D 403/04 (2013.01); C07D 491/107 (2013.01); C07D 513/04 (2013.01); A61K 9/0014 (2013.01); A61K 31/40 (2013.01); A61K 31/436 (2013.01); A61K 31/519 (2013.01); A61K 31/5513 (2013.01); G16C 20/50 (2019.02);
Abstract
The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins—mitochondrial-based therapeutic compounds having anti-cancer and antibiotic properties—to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitochondrial inhibitors to provide anti-aging benefits. Specific mitoriboscin compounds and groups of mitoriboscins are also disclosed.